An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer

Cancer Research

Volumn 62, Issue 16, 2002, Pages 4678-4684

  Guo, YongJing ^a   Mazar, Andrew P ^b,c   Lebrun, Jean Jacques ^a   Rabbani, Shafaat A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ngstrom Pharmaceuticals Inc   (United States)

^c Attenuon LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; MATRIGEL; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; EVALUATION; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT; RAT STRAIN; TUMOR CELL DESTRUCTION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL DIVISION; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; RATS; RATS, INBRED F344; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037102259     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. The role of the plasminogen activation system in angiogenesis and metastasis
2. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B. D, and L.) in primary breast cancer reflects effects of adjuvant systemic therapy
3. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model
4. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins
5. A proenzyme form of human urokinase
6. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases
7. Heparin binding to the urokinase kringle domain
8. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor
9. Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility
10. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo
11. The etiopathogenesis of breast cancer prevention
12. Model systems for the study of estrogen action in tissue culture
13. Effective tamoxifen therapy of breast cancer involves both anti-proliferative and pro-apoptotic changes
14. Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients
15. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer
16. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
17. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer
18. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
19. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: Role of DNA methylation
20. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts
21. Structural requirements for the growth factor activity of the aminoterminal domain of urokinase
22. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428
23. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: An alternative to [3H]thymidine incorporation assay
24. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat
25. TGF β signals through a heteromeric protein kinase receptor complex
26. Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo
27. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
28. TGF-β signaling in tumor suppression and cancer progression
29. Inducible expression of transforming growth factor β1 in papillomas causes rapid metastasis
30. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice
31. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies
32. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin
33. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer
34. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1
35. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells
36. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype
37. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression
38. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)containing NADPH oxidase